Adaptive Biotechnologies Corp chief scientific officer Harlan S. Robins exercised a fully vested stock option for 284,800 shares of common stock at $6.55 per share and sold 492,400 shares in two transactions at weighted-average prices of $21.72 and $22.12 on July 21, 2026.
All reported trades were effected under a Rule 10b5-1 trading plan adopted on March 13, 2026.
ADPT reports that Harlan Robins has filed a notice to potentially sell common stock through Goldman Sachs & Co. LLC, with an anticipated sale date of July 21, 2026 on NASD. The securities information section lists figures of 492,400, 11,118,392 and 160,044,392 tied to this common stock entry.
The filing also lists planned sales sourced from equity compensation: common stock acquired on March 10, 2026 as compensation via performance awards in the amount of 207,600, and common stock acquired on February 7, 2018 via stock options in the amount of 284,800 through a cashless exercise/same-day sale structure. In the past three months, entries show common stock sales on June 15, June 16 and July 2, 2026 in amounts including 100,000, 6,160, 136,240 and 250,000.
Susan Bobulsky, Chief Commercial Officer, MRD of Adaptive Biotechnologies Corp, sold 5,000 shares of Common Stock on July 16, 2026 at $23.00 per share. The sale was made under a Rule 10b5-1 trading plan adopted on December 16, 2025, and she now directly holds 401,288 shares of Common Stock.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo exercised employee stock options covering 105,762 common shares at exercise prices of $7.80, $8.46 and $12.14, and sold 105,762 shares of common stock at a weighted average price of $22.59 on July 15, 2026.
After these transactions, he directly held 230,713 common shares and indirectly held 2,500 shares through his spouse. All transactions were effected under a Rule 10b5-1 trading plan adopted on September 15, 2025.
Susan Bobulsky plans to sell 5,000 shares of ADPT common stock, with an estimated aggregate value of $114,500 and a planned sale date of July 16, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services. The shares come from previously exercised stock options, and recent 10b5-1 plan sales between June 4 and July 1, 2026 are also listed, including trades of 487, 5,000 and 11,000 shares.
Adaptive Biotechnologies Corp Chief Scientific Officer Harlan S. Robins reported open-market sales of 386,240 shares of common stock on July 2, 2026. The sales occurred in two blocks at weighted-average prices of $21.74 and $22.45 per share.
The transactions were executed under a pre-arranged Rule 10b5-1 trading plan adopted on March 13, 2026, indicating they were scheduled in advance rather than timed discretionarily. After these sales, he continues to hold a significant direct equity position in the company.
Adaptive Biotechnologies Corp Chief People Officer Francis Lo reported option exercises and pre-planned share sales. On July 1–2, 2026, Lo exercised stock options covering 75,621 shares of common stock and sold 95,842 shares in open-market transactions at weighted average prices in the low $20s per share.
The filing states these trades were made under a Rule 10b5-1 trading plan adopted on September 15, 2025, indicating they were pre-scheduled. After the transactions, Lo directly held 230,713 shares of common stock, plus 2,500 shares held indirectly through a spouse.
Adaptive Biotechnologies Corp Chief Commercial Officer, MRD, Susan Bobulsky reported an open-market sale of 487 shares of common stock at $22.00 per share. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan adopted on December 16, 2025, and she continues to hold 406,288 shares directly after the sale.
ADPT: Form 144 notice reporting proposed and recent sales of Common Stock by Harlan Robins. The filing lists multiple grant/award acquisition entries (Restricted Stock Units and Performance Awards) with grant dates from 03/04/2021 through 03/07/2026. It discloses securities sold in the past three months: 100,000 shares on 06/15/2026 (value shown 1,737,460), 6,160 shares on 06/16/2026 (value shown 110,945.91), and 10,000 shares on 04/08/2026 (value shown 148,323.94).
Francis Lo reported proposed dispositions of Common Stock on a Form 144. The notice lists an item described as an Exercise of Stock Options for 179,039 shares dated 07/01/2026 and a grant of 20,221 Restricted Stock Units dated 03/04/2025. The filing also records prior 10b5-1 sales of 39,741 shares on 06/04/2026 for $695,070.09 and 22,564 shares on 04/08/2026 for $339,941.67.